Risk factor
Very poor trading liquidity
Profitability factor
Very favourable analyst view
About
Paxman AB (publ), together with its subsidiaries, develops and sells Paxman scalp cooling system to minimize hair loss in connection with chemotherapy treatment in Europe, the United States, Mexico, Japan, Oceania, rest of Asia, and South and Central America. It serves various cancer centers and hospitals. The comapny has a research collaboration agreement with National...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, overvalued
Target Price
The average target price of PAX.ST is 95 and suggests 94% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell